Intermittent preventive treatment for malaria in infants
Citation: Esu EB, Oringanje C, Meremikwu MM. Intermittent preventive treatment for malaria in infants. Cochrane Database of Systematic Reviews 2019, Issue 12. Art. No.: CD011525.
Giving sulfadoxine‐pyrimethamine (SP) as preventive antimalarial treatment to infants probably reduces the risk of clinical malaria, anaemia, and hospital admissions in the African countries. However, this effect was attenuated in more recent studies. Giving artemisinin‐based combination therapy (ACT) as preventive antimalarial treatment to infants may reduce the risk of clinical malaria. It may also reduce the proportion of infants with malaria parasites in their blood.
Intermittent preventive treatment could help prevent malaria in infants (IPTi) living in areas of moderate to high malaria transmission in sub‐Saharan Africa. The World Health Organization (WHO) policy recommended IPTi in 2010, but its adoption in countries has been limited. This Cochrane review aimed to find out if administering repeated doses of antimalarial treatment to infants living in sub‐Saharan Africa can prevent malaria. Results were analysed from 12 relevant studies conducted between 1999 and 2013 that addressed this question in infants (defined as young children aged between 1 to 12 months).
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on humanitarian response but may not have the time, initially, to read the report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence presented within it is relevant to their decision-making, they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.